Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
Volume 4.26M
Average 2.07M
QGEN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Qiagen N.V.NYSE: QGEN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows in line with its trailing trend
Q2 FY2026 research & development of $50.43M rose 5.6% year over year, in line with the +5.5% change in trailing-twelve-month research & development. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -0.4% a year.
Context
- Research & development amounted to 9.0% of revenue in FY2025, down 0.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.6% holds above the trailing-twelve-month pace of +5.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 187.52M USD
- Year-over-year change
- -3.1%
- 4-year CAGR
- -0.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 187.52M | -3.1% |
| FY2024 | 2024-12-31 | 193.49M | -2.5% |
| FY2023 | 2023-12-31 | 198.51M | +4.6% |
| FY2022 | 2022-12-31 | 189.86M | -0.1% |
| FY2021 | 2021-12-31 | 189.96M | — |
Research & Development vs competitors
How QGEN compares with its peers on the latest reported figures
- QGEN's LTM Jun 2026 research & development of $194.67M is the 8th highest of the 11 companies compared; the peer median is $241.82M.
- Its year-over-year change of +5.5% is the 4th highest of 11, against a peer median of +1.8%.
- Research & development amounts to 9.3% of revenue for QGEN, versus a peer median of 7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Sep 2026 | $222.54M | -10.9% | -3.5% | 36.0% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Jun 2026 | $55.23M | +14.4% | +7.2% | 7.0% | |
| LTM Jun 2026 | $21.15M | +13.2% | +8.3% | 10.1% | |
| Peer median (excluding QGEN) | $241.82M | +1.8% | +0.4% | 7.6% | |
Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B |
| Cost of Revenue | 800.84M | 756.96M | 731.62M | 1.01B | 798.5M |
| Gross Profit | 1.45B | 1.38B | 1.23B | 967.35M | 1.29B |
| Gross Margin | 64.4% | 64.7% | 62.8% | 48.9% | 61.8% |
| Research & Development | 189.96M | 189.86M | 198.51M | 193.49M | 187.52M |
| Selling, General & Admin | 584.47M | 603.95M | 579.17M | 564.36M | 583.67M |
| Operating Expenses | 820.74M | 853.1M | 823.75M | 869.64M | 771.19M |
| Depreciation & Amortization | 214.93M | 208.4M | 205.34M | 203.27M | 193.75M |
| EBITDA | 895.24M | 779.36M | 688.56M | 368.26M | 717.27M |
| EBITDA Margin | 39.8% | 36.4% | 35.0% | 18.6% | 34.3% |
| Operating Income | 630.08M | 531.46M | 409.94M | 97.71M | 520.31M |
| Operating Margin | 28.0% | 24.8% | 20.9% | 4.9% | 24.9% |
| Interest Income | 9.56M | 32.76M | 78.99M | 68.02M | 64.32M |
| Interest Expense | 54.48M | 58.36M | 53.41M | 43.84M | 33.26M |
| Other Income / Expenses | (4.25M) | (18.86M) | 19.87M | 23.44M | (30.04M) |
| Income Before Tax | 625.83M | 512.6M | 429.81M | 121.15M | 490.27M |
| Pre-Tax Margin | 27.8% | 23.9% | 21.9% | 6.1% | 23.5% |
| Income Tax Expense | 113.23M | 89.39M | 88.51M | 37.56M | 65.39M |
| Net Income | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Net Margin | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| EPS (Basic) | 2.52 | 2.08 | 1.67 | 0.39 | 2.04 |
| EPS (Diluted) | 2.47 | 2.05 | 1.65 | 0.38 | 2.04 |
| Weighted Avg Shares | 221.14M | 220.75M | 217.49M | 216.44M | 207.94M |
| Weighted Avg Shares (Diluted) | 225.07M | 223.23M | 217.49M | 218.48M | 207.94M |
Qiagen N.V.
NYSE:QGEN
Intrinsic Alpha fair value
Locked
Current Price
$49.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.